The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

• Main Authors: Alana Aragón-Herrera (Author), Manuel Otero-Santiago (Author), Laura Anido-Varela (Author), Sandra Moraña-Fernández (Author), Manuel Campos-Toimil (Author), Tomás García-Caballero (Author), Luis Barral (Author), Estefanía Tarazón (Author), Esther Roselló-Lletí (Author), Manuel Portolés (Author), Oreste Gualillo (Author), Isabel Moscoso (Author), Ricardo Lage (Author), José Ramón González-Juanatey (Author), Sandra Feijóo-Bandín (Author), Francisca Lago (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have s...